2016 年的期刊文章 · 第 8 页

共 1345 篇,按发表时间排,新的在前,每页 40 篇。这一页是 2016-09-19 到 2016-08-31。

按期刊、按主题看 →

第 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 页

SMMR Diagnostics & Prediction Longitudinal Data Latent Variables & Mixtures · 发表于 2016-09-19

Does ignoring clustering in multicenter data influence the performance of prediction models? A simulation study

L Wynants, Y Vergouwe, S Van Huffel, D Timmerman, B Van Calster

摘要

Clinical risk prediction models are increasingly being developed and validated on multicenter datasets. In this article, we present a comprehensive framework for the evaluation of the predictive performance of prediction models at the center level and the population level, considering population-averaged predictions, center-specific predictions, and predictions assuming an average random center effect. We demonstrated in a simulation study that calibration slopes do not only deviate from one because of over- or underfitting of patterns in the development dataset, but also as a result of the choice of the model (standard versus mixed effects logistic regression), the type of predictions (marginal versus conditional versus assuming an average random effect), and the level of model validation (center versus population). In particular, when data is heavily clustered (ICC 20%), center-specific predictions offer the best predictive performance at the population level and the center level. We recommend that models should reflect the data structure, while the level of model validation should reflect the research question.

SMMR Other · 发表于 2016-09-19

Control limits to identify outlying hospitals based on risk-stratification

Valentin Rousson, Marie-Annick Le Pogam, Yves Eggli

摘要

Outcome indicators are routinely used to compare hospitals with respect to quality of care. Indicators might be based on observed proportions of adverse events (binary outcomes) or observed averages of e.g. lengths or costs of hospital stays (continuous outcomes). These observed values are compared with expected ones in an average hospital, which might be estimated from a reference sample and should be appropriately adjusted for the case mix of patients. One possibility to achieve a reliable adjustment is to stratify the patients according to their risks, where each patient belongs to one and only one stratum. Control limits calculated under the null hypothesis of an average hospital, allowing to decide whether a discrepancy between an observed and an expected value might be explained by chance or not, are then plotted around the indicator, such that hospitals falling above those control limits are detected as being statistically worse than an average hospital. Calculation of valid control limits is however not always obvious. In this article, we propose a simple and unified framework to calculate such control limits when adjustment is based on stratification, where we allow to distinguish and disentangle the variability explained by stratification and the variability due to chance, where we take into account the uncertainty about the estimation of the expected values, and where it is possible not only to detect those hospitals which are statistically worse, but also those which are statistically much worse than an average hospital. The method applies both to binary and continuous outcomes and is illustrated on Swiss hospital discharge data.

SiM Longitudinal Data · 发表于 2016-09-19

Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials

Zhiguo Li

摘要

In sequential multiple assignment randomized trials, longitudinal outcomes may be the most important outcomes of interest because this type of trials is usually conducted in areas of chronic diseases or conditions. We propose to use a weighted generalized estimating equation (GEE) approach to analyzing data from such type of trials for comparing two adaptive treatment strategies based on generalized linear models. Although the randomization probabilities are known, we consider estimated weights in which the randomization probabilities are replaced by their empirical estimates and prove that the resulting weighted GEE estimator is more efficient than the estimators with true weights. The variance of the weighted GEE estimator is estimated by an empirical sandwich estimator. The time variable in the model can be linear, piecewise linear, or more complicated forms. This provides more flexibility that is important because, in the adaptive treatment setting, the treatment changes over time and, hence, a single linear trend over the whole period of study may not be practical. Simulation results show that the weighted GEE estimators of regression coefficients are consistent regardless of the specification of the correlation structure of the longitudinal outcomes. The weighted GEE method is then applied in analyzing data from the Clinical Antipsychotic Trials of Intervention Effectiveness. Copyright © 2016 John Wiley & Sons, Ltd.

SMMR Survival Analysis · 发表于 2016-09-19

Association analysis of successive events data in the presence of competing risks

Xiaotian Chen, Yu Cheng, Ellen Frank, David J Kupfer

摘要

We aim to close a methodological gap in analyzing durations of successive events that are subject to induced dependent censoring as well as competing-risk censoring. In the Bipolar Disorder Center for Pennsylvanians study, some patients who managed to recover from their symptomatic entry later developed a new depressive or manic episode. It is of great clinical interest to quantify the association between time to recovery and time to recurrence in patients with bipolar disorder. The estimation of the bivariate distribution of the gap times with independent censoring has been well studied. However, the existing methods cannot be applied to failure times that are censored by competing causes such as in the Bipolar Disorder Center for Pennsylvanians study. Bivariate cumulative incidence function has been used to describe the joint distribution of parallel event times that involve multiple causes. To the best of our knowledge, however, there is no method available for successive events with competing-risk censoring. Therefore, we extend the bivariate cumulative incidence function to successive events data, and propose non-parametric estimators of the bivariate cumulative incidence function and the related conditional cumulative incidence function. Moreover, an odds ratio measure is proposed to describe the cause-specific dependence, leading to the development of a formal test for independence of successive events. Simulation studies demonstrate that the estimators and tests perform well for realistic sample sizes, and our methods can be readily applied to the Bipolar Disorder Center for Pennsylvanians study.

JRSSB High-Dimensional Testing & Uncertainty Genetics & Omics · 发表于 2016-09-16

EigenPrism: Inference for High Dimensional Signal-to-Noise Ratios

Lucas Janson, Rina Foygel Barber, Emmanuel Candès

摘要

Summary: Consider the following three important problems in statistical inference: constructing confidence intervals for the error of a high dimensional (p > n) regression estimator, the linear regression noise level and the genetic signal-to-noise ratio of a continuous-valued trait (related to the heritability). All three problems turn out to be closely related to the little-studied problem of performing inference on the l2-norm of the signal in high dimensional linear regression. We derive a novel procedure for this, which is asymptotically correct when the covariates are multivariate Gaussian and produces valid confidence intervals in finite samples as well. The procedure, called EigenPrism, is computationally fast and makes no assumptions on coefficient sparsity or knowledge of the noise level. We investigate the width of the EigenPrism confidence intervals, including a comparison with a Bayesian setting in which our interval is just 5% wider than the Bayes credible interval. We are then able to unify the three aforementioned problems by showing that EigenPrism with only minor modifications can make important contributions to all three. We also investigate the robustness of coverage and find that the method applies in practice and in finite samples much more widely than just the case of multivariate Gaussian covariates. Finally, we apply EigenPrism to a genetic data set to estimate the genetic signal-to-noise ratio for a number of continuous phenotypes.

SiM Longitudinal Data Bayesian Methods Clinical Trials · 发表于 2016-09-15

A Bayesian dose‐finding design incorporating toxicity data from multiple treatment cycles

Jun Yin, Rui Qin, Monia Ezzalfani, Daniel J. Sargent, Sumithra J. Mandrekar

摘要

Phase I oncology trials are designed to identify a safe dose with an acceptable toxicity profile. The dose is typically determined based on the probability of severe toxicity observed during the first treatment cycle, although patients continue to receive treatment for multiple cycles. In addition, the toxicity data from multiple types and grades are typically summarized into a single binary outcome of dose‐limiting toxicity. A novel endpoint, the total toxicity profile, was previously developed to account for the multiple toxicity types and grades. In this work, we propose to account for longitudinal repeated measures of total toxicity profile over multiple treatment cycles, accounting for cumulative toxicity during dosing‐finding. A linear mixed model was utilized in the Bayesian framework, with addition of Bayesian risk functions for decision‐making in dose assignment. The performance of this design is evaluated using simulation studies and compared with the previously proposed quasi‐likelihood continual reassessment method (QLCRM) design. Twelve clinical scenarios incorporating four different locations of maximum tolerated dose and three different time trends (decreasing, increasing, and no effect) were investigated. The proposed repeated measures design was comparable with the QLCRM when only cycle 1 data were utilized in dose‐finding; however, it demonstrated an improvement over the QLCRM when data from multiple cycles were used across all scenarios. Copyright © 2016 John Wiley & Sons, Ltd.

SiM Clinical Trials · 发表于 2016-09-14

Designs for phase I trials in ordered groups

Mark R. Conaway, Nolan A. Wages

摘要

We propose a new design for dose finding for cytotoxic agents in two ordered groups of patients. By ordered groups, we mean that prior to the study there is clinical information that would indicate that for a given dose one group would be more susceptible to toxicities than patients in the other group. The designs are evaluated relative to two previously proposed designs for ordered groups over a range of scenarios generated randomly from a family of dose‐toxicity curves. Copyright © 2016 John Wiley & Sons, Ltd.

SiM Bayesian Methods · 发表于 2016-09-13

Control charts for monitoring accumulating adverse event count frequencies from single and multiple blinded trials

A. Lawrence Gould

摘要

Conventional practice monitors accumulating information about drug safety in terms of the numbers of adverse events reported from trials in a drug development program. Estimates of between-treatment adverse event risk differences can be obtained readily from unblinded trials with adjustment for differences among trials using conventional statistical methods. Recent regulatory guidelines require monitoring the cumulative frequency of adverse event reports to identify possible between-treatment adverse event risk differences without unblinding ongoing trials. Conventional statistical methods for assessing between-treatment adverse event risks cannot be applied when the trials are blinded. However, CUSUM charts can be used to monitor the accumulation of adverse event occurrences. CUSUM charts for monitoring adverse event occurrence in a Bayesian paradigm are based on assumptions about the process generating the adverse event counts in a trial as expressed by informative prior distributions. This article describes the construction of control charts for monitoring adverse event occurrence based on statistical models for the processes, characterizes their statistical properties, and describes how to construct useful prior distributions. Application of the approach to two adverse events of interest in a real trial gave nearly identical results for binomial and Poisson observed event count likelihoods. Copyright © 2016 John Wiley & Sons, Ltd. *(abstract via PubMed)*

SiM Survival Analysis · 发表于 2016-09-13

A special case of reduced rank models for identification and modelling of time varying effects in survival analysis

Aris Perperoglou

摘要

Flexible survival models are in need when modelling data from long term follow‐up studies. In many cases, the assumption of proportionality imposed by a Cox model will not be valid. Instead, a model that can identify time varying effects of fixed covariates can be used. Although there are several approaches that deal with this problem, it is not always straightforward how to choose which covariates should be modelled having time varying effects and which not. At the same time, it is up to the researcher to define appropriate time functions that describe the dynamic pattern of the effects. In this work, we suggest a model that can deal with both fixed and time varying effects and uses simple hypotheses tests to distinguish which covariates do have dynamic effects. The model is an extension of the parsimonious reduced rank model of rank 1. As such, the number of parameters is kept low, and thus, a flexible set of time functions, such as b‐splines, can be used. The basic theory is illustrated along with an efficient fitting algorithm. The proposed method is applied to a dataset of breast cancer patients and compared with a multivariate fractional polynomials approach for modelling time‐varying effects. Copyright © 2016 John Wiley & Sons, Ltd.

Biometrics Survival Analysis Nonparametric & Semiparametric · 发表于 2016-09-09

Quantile Association for Bivariate Survival Data

Ruosha Li, Yu Cheng, Qingxia Chen, Jason Fine

摘要

Summary: Bivariate survival data arise frequently in familial association studies of chronic disease onset, as well as in clinical trials and observational studies with multiple time to event endpoints. The association between two event times is often scientifically important. In this article, we examine the association via a novel quantile association measure, which describes the dynamic association as a function of the quantile levels. The quantile association measure is free of marginal distributions, allowing direct evaluation of the underlying association pattern at different locations of the event times. We propose a nonparametric estimator for quantile association, as well as a semiparametric estimator that is superior in smoothness and efficiency. The proposed methods possess desirable asymptotic properties including uniform consistency and root-n convergence. They demonstrate satisfactory numerical performances under a range of dependence structures. An application of our methods suggests interesting association patterns between time to myocardial infarction and time to stroke in an atherosclerosis study.

SiM Other · 发表于 2016-09-07

A novel chi‐square statistic for detecting group differences between pathways in systems epidemiology

Zhongshang Yuan, Jiadong Ji, Tao Zhang, Yi Liu, Xiaoshuai Zhang, Wei Chen, Fuzhong Xue

摘要

Traditional epidemiology often pays more attention to the identification of a single factor rather than to the pathway that is related to a disease, and therefore, it is difficult to explore the disease mechanism. Systems epidemiology aims to integrate putative lifestyle exposures and biomarkers extracted from multiple omics platforms to offer new insights into the pathway mechanisms that underlie disease at the human population level. One key but inadequately addressed question is how to develop powerful statistics to identify whether one candidate pathway is associated with a disease. Bearing in mind that a pathway difference can result from not only changes in the nodes but also changes in the edges, we propose a novel statistic for detecting group differences between pathways, which in principle, captures the nodes changes and edge changes, as well as simultaneously accounting for the pathway structure simultaneously. The proposed test has been proven to follow the chi‐square distribution, and various simulations have shown it has better performance than other existing methods. Integrating genome‐wide DNA methylation data, we analyzed one real data set from the Bogalusa cohort study and significantly identified a potential pathway, Smoking → SOCS3 → PIK3R1, which was strongly associated with abdominal obesity. The proposed test was powerful and efficient at identifying pathway differences between two groups, and it can be extended to other disciplines that involve statistical comparisons between pathways. The source code in R is available on our website. Copyright © 2016 John Wiley & Sons, Ltd.

Biometrics Causal Inference Clinical Trials · 发表于 2016-09-06

Sequential Multiple Assignment Randomization Trials with Enrichment Design

Ying Liu, Yuanjia Wang, Donglin Zeng

摘要

Summary: Sequential multiple assignment randomization trial (SMART) is a powerful design to study Dynamic Treatment Regimes (DTRs) and allows causal comparisons of DTRs. To handle practical challenges of SMART, we propose a SMART with Enrichment (SMARTER) design, which performs stage-wise enrichment for SMART. SMARTER can improve design efficiency, shorten the recruitment period, and partially reduce trial duration to make SMART more practical with limited time and resource. Specifically, at each subsequent stage of a SMART, we enrich the study sample with new patients who have received previous stages’ treatments in a naturalistic fashion without randomization, and only randomize them among the current stage treatment options. One extreme case of the SMARTER is to synthesize separate independent single-stage randomized trials with patients who have received previous stage treatments. We show data from SMARTER allows for unbiased estimation of DTRs as SMART does under certain assumptions. Furthermore, we show analytically that the efficiency gain of the new design over SMART can be significant especially when the dropout rate is high. Lastly, extensive simulation studies are performed to demonstrate performance of SMARTER design, and sample size estimation in a scenario informed by real data from a SMART study is presented.

Biometrics Latent Variables & Mixtures High-Dimensional · 发表于 2016-09-06

Screening and Clustering of Sparse Regressions with Finite Non-Gaussian Mixtures

Jian Zhang

摘要

Summary: This article proposes a method to address the problem that can arise when covariates in a regression setting are not Gaussian, which may give rise to approximately mixture-distributed errors, or when a true mixture of regressions produced the data. The method begins with non-Gaussian mixture-based marginal variable screening, followed by fitting a full but relatively smaller mixture regression model to the selected data with help of a new penalization scheme. Under certain regularity conditions, the new screening procedure is shown to possess a sure screening property even when the population is heterogeneous. We further prove that there exists an elbow point in the associated scree plot which results in a consistent estimator of the set of active covariates in the model. By simulations, we demonstrate that the new procedure can substantially improve the performance of the existing procedures in the content of variable screening and data clustering. By applying the proposed procedure to motif data analysis in molecular biology, we demonstrate that the new method holds promise in practice.

Biometrics Survival Analysis · 发表于 2016-09-06

Residual-Based Model Diagnosis Methods for Mixture Cure Models

Yingwei Peng, Jeremy M. G. Taylor

摘要

Summary: Model diagnosis, an important issue in statistical modeling, has not yet been addressed adequately for cure models. We focus on mixture cure models in this work and propose some residual-based methods to examine the fit of the mixture cure model, particularly the fit of the latency part of the mixture cure model. The new methods extend the classical residual-based methods to the mixture cure model. Numerical work shows that the proposed methods are capable of detecting lack-of-fit of a mixture cure model, particularly in the latency part, such as outliers, improper covariate functional form, or nonproportionality in hazards if the proportional hazards assumption is employed in the latency part. The methods are illustrated with two real data sets that were previously analyzed with mixture cure models.

Biometrics Testing & Uncertainty · 发表于 2016-09-06

Multiple Testing with Heterogeneous Multinomial Distributions

Joshua Habiger, David Watts, Michael Anderson

摘要

Summary: Standard false discovery rate (FDR) procedures can provide misleading inference when testing multiple null hypotheses with heterogeneous multinomial data. For example, in the motivating study the goal is to identify species of bacteria near the roots of wheat plants (rhizobacteria) that are moderately or strongly associated with productivity. However, standard procedures discover the most abundant species even when their association is weak and fail to discover many moderate and strong associations when the species are not abundant. This article provides a new FDR-controlling method based on a finite mixture of multinomial distributions and shows that it tends to discover more moderate and strong associations and fewer weak associations when the data are heterogeneous across tests. The new method is applied to the rhizobacteria data and performs favorably over competing methods.

Biometrics Diagnostics & Prediction Bayesian Methods Latent Variables & Mixtures · 发表于 2016-09-06

Estimation of Diagnostic Accuracy of a Combination of Continuous Biomarkers Allowing for Conditional Dependence Between the Biomarkers and the Imperfect Reference-Test

Leandro García Barrado, Els Coart, Tomasz Burzykowski

摘要

Summary: Estimating biomarker-index accuracy when only imperfect reference-test information is available is usually performed under the assumption of conditional independence between the biomarker and imperfect reference-test values. We propose to define a latent normally-distributed tolerance-variable underlying the observed dichotomous imperfect reference-test results. Subsequently, we construct a Bayesian latent-class model based on the joint multivariate normal distribution of the latent tolerance and biomarker values, conditional on latent true disease status, which allows accounting for conditional dependence. The accuracy of the continuous biomarker-index is quantified by the AUC of the optimal linear biomarker-combination. Model performance is evaluated by using a simulation study and two sets of data of Alzheimer's disease patients (one from the memory-clinic-based Amsterdam Dementia Cohort and one from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database). Simulation results indicate adequate model performance and bias in estimates of the diagnostic-accuracy measures when the assumption of conditional independence is used when, in fact, it is incorrect. In the considered case studies, conditional dependence between some of the biomarkers and the imperfect reference-test is detected. However, making the conditional independence assumption does not lead to any marked differences in the estimates of diagnostic accuracy.

SMMR Missing Data & Measurement Error Longitudinal Data · 发表于 2016-09-05

Relative efficiency of joint-model and full-conditional-specification multiple imputation when conditional models are compatible: The general location model

Shaun R Seaman, Rachael A Hughes

摘要

Estimating the parameters of a regression model of interest is complicated by missing data on the variables in that model. Multiple imputation is commonly used to handle these missing data. Joint model multiple imputation and full-conditional specification multiple imputation are known to yield imputed data with the same asymptotic distribution when the conditional models of full-conditional specification are compatible with that joint model. We show that this asymptotic equivalence of imputation distributions does not imply that joint model multiple imputation and full-conditional specification multiple imputation will also yield asymptotically equally efficient inference about the parameters of the model of interest, nor that they will be equally robust to misspecification of the joint model. When the conditional models used by full-conditional specification multiple imputation are linear, logistic and multinomial regressions, these are compatible with a restricted general location joint model. We show that multiple imputation using the restricted general location joint model can be substantially more asymptotically efficient than full-conditional specification multiple imputation, but this typically requires very strong associations between variables. When associations are weaker, the efficiency gain is small. Moreover, full-conditional specification multiple imputation is shown to be potentially much more robust than joint model multiple imputation using the restricted general location model to mispecification of that model when there is substantial missingness in the outcome variable.

SiM Diagnostics & Prediction Econometrics & Economics Causal Inference · 发表于 2016-09-04

Robust empirical calibration of p‐values using observational data

Martijn J. Schuemie, George Hripcsak, Patrick B. Ryan, David Madigan, Marc A. Suchard

摘要

In our previous paper 1, we proposed empirical calibration of p-values as a strategy for mitigating risk of systematic error when estimating average treatment effects from observational studies. By estimating the effect of exposure on outcomes across a collection of settings where the exposure is not believed to cause the outcome (negative controls), one can estimate an empirical null distribution of the exposure effect and compute calibrated p-values that take both random and systematic error into account. Gruber and Tchetgen 2 recently published a simulation that is intended to demonstrate the theoretical scenario in which empirical calibration may not be recommended. We welcome a thoughtful debate about the theoretical and empirical underpinnings of empirical calibration and share an enthusiasm to develop practical solutions that can be made broadly applicable to all observational analyses as a means of generating more reliable evidence. However, as we explain in more detail later, we would like to highlight and challenge the premise of some of the concerns raised by Gruber and Tchetgen and demonstrate how our empirical findings support empirical calibration as a robust approach to Type I error control. We believe their simulations are not realistic: the simulated estimates of negative controls showed severe bias with an odds ratio (OR) of 3, and perhaps more important, this bias was also simulated to be unusually homogeneous across the sample of negative controls. No one would continue their analysis after observing such estimates for their negative controls, and in all our real-world experiments using calibration, we have never seen such bias or homogeneity of negative controls. They confirm our findings that nominal p-values are strikingly and perhaps dangerously optimistic but recommend that we continue to use them. We believe that p-value calibration should be carried out, and the results should be reported. Previously, we performed a leave-one-out validation study that provides strong support for these points. In this analysis, for each negative control, we computed the empirical null distribution using all other controls and calibrated the p-value of the held-out control using that distribution. Results showed good calibration properties (e.g. approximately 5% of the negative controls had calibrated p < 0.05 as expected) despite the fact that negative controls represented a wide range of drug-outcome pairs, with potentially very different sources of bias. (Note that we recommend that people always perform this leave-one-out analysis, because in specific cases the previously mentioned assumptions could be violated.) The empirical calibration approach requires an exchangeability assumption that there is some level of exchangeability between the negative controls and the drug-outcome hypothesis of interest. Our leave-one-out evaluation shows that there is exchangeability within the negative controls; for any negative control, the others can be used to calibrate its p-value accurately. But we have no evidence that this exchangeability holds for drug-outcome pairs outside the set of negative controls. Gruber and Tchetgen's main challenge is to this assumption. They argue that theoretically all negative controls could show strong bias in one direction, while the hypothesis of interest shows no bias or the other way around, in which case empirical calibration will fail. They use simulations to demonstrate this point. In their 'medium' simulation, all negative controls show strong bias, with a mean OR of 3, whereas the hypotheses of interest all have small bias, as shown in Figure 1. Gruber and Tchetgen provide no evidence that such conditions happen in real applications. They do, however, motivate these conditions by noting that when using negative exposure controls for a newly marketed drug that 'for example, uptake of a newly marketed drug, prevalence of off-label drug use, availability of alternative treatment options and physician prescribing behaviors typically changes in the years following drug approval.' To frame this in their simulation, Gruber and Tchetgen assume that a particular study design (e.g. a new-user cohort design using propensity score adjustment) would be almost unbiased for a newly marketed drug (the hypothesis of interest) but would systematically produce an OR of 3 for negative control drugs that have been on the market longer. They do not discuss the consequence that a reasonable researcher would become suspicious when observing OR = 3 for all negative controls and might decide to discard the analytic approach. In practice, negative controls are inherently heterogeneous. Figure 2 shows the distribution of negative control estimates from a new-user cohort study 3 comparing the risk of gastrointestinal (GI) bleeds in celecoxib versus diclofenac users, where we use negative outcome controls (i.e. outcomes not believed to be causally related to either drug) (see the Supporting information for details of the study). In this particular analysis, we make no adjustments for confounding, and we observe large bias as expected. In this real-world example the distribution of negative controls looks nothing like the simulation. Overall, negative controls are positively biased as one would expect; celecoxib tends to be prescribed to a frailer population than diclofenac. But much more pronounced is the large variability in bias, both in positive and negative direction. Figure 3 shows the results of the leave-one-out cross-validation of the negative controls, demonstrating superior calibration for the empirically calibrated p-value compared with the traditional p-value. Even though negative controls are very different from one another (negative controls includes 'ingrowing nail', 'allergic rhinitis' and also 'obsessive compulsive disorder'), we achieve better calibration than when using traditional p-value computation, suggesting the exchangeability assumption holds within the set of negative controls. We have no evidence that these performance characteristics apply for exposure-outcome pairs outside the set of negative controls. However, given the large heterogeneity in the types of controls, ranging from infectious diseases to mental disorders and accompanying heterogeneity in underlying confounding, it is likely the bias of the hypothesis of interest is represented to some extent by the negative controls. Furthermore, the observed empirical null distribution is far wider than those simulated by Gruber and Tchetgen, making it more likely there is at least some overlap with the bias distribution for the hypotheses of interest. Even though the calibration performance may not be perfect, it is unlikely to be as bad as simulated by Gruber and Tchetgen, where the two distributions were far apart as shown in Figure 1. Gruber and Tchetgen also lament that correcting type I error by p-value calibration can drastically increase type II error. As noted in our original paper: 'The method proposed here aims to correct the type I error (erroneously rejecting the null hypothesis) level, most likely at the cost of vastly increasing the number of type II errors (erroneously rejecting the alternative hypothesis).' 1 There is no free lunch: we cannot have both low type I and type II error in the face of a strongly biased estimator, such as the one depicted in Figure 2. In this plot, it is clear that no matter how large the sample size, no estimate between 0.6 and 2.1 will ever reach statistical significance when using p-value calibration. Even when the null hypothesis is not true, we will most likely fail to reject it. This trade-off is not a drawback of the calibration method, but instead exposes a limitation of the observational data and the analysis design being employed. With a less biased estimator, we could achieve both lower type I and type II error. For example, Figure 4 reports the same results as Figure 2 but now using an adjusted analysis using propensity score matching. In this analysis, there is little bias, and the calibrated p-value does not differ much from the traditional p-value. Figure 5 shows that in a leave-one-out validation, both p-values are indeed comparable. It is worthwhile to note that without examining negative controls in the crude analysis, we would not have unearthed the limitations of that design. Gruber and Tchetgen challenge the assumption of exchangeability, arguing that newly marketed drugs may have inherently different bias than exposure controls, which are typically older drugs. However, in their simulations, they underestimate the variability in the bias observed for negative controls in the real world. Given the width of the estimated empirical null distribution, it is likely that the bias of the hypothesis of interest is included in this distribution. Therefore, even if the exchangeability assumption is violated, and Gruber and Tchetgen have provided no evidence that this is the case, this most likely would mean the calibrated p-value would err on the conservative side, leading to larger p-values and making it harder to reject the null. As the mean and standard deviation of the empirical null distribution approach zero, as can be seen in Figure 4, we interpret this as meaning that the method is becoming insensitive to confounding in the data. A consequence is that the calibrated p-value is becoming less sensitive to the exchangeability assumption. In other words, if large bias and variability in bias is observed for the negative controls, one should be aware there is a possibility one's calibrated p-values are too conservative. If small or no bias is observed, we should feel confident the calibrated p-value is approximately correct. It should also be noted that Gruber and Tchetgen's criticism only applies to exposure controls for new drugs, in which case one could elect to use outcome controls instead. We fully agree with Gruber and Tchetgen that empirical calibration can lead to a large increase in type II error when using a strongly biased estimator. It seems Gruber and Tchetgen suggest that if one is truly concerned with only type II error, one should forego calibration and accept that the p-value does not represent any meaningful statistic. But we think that in this case a better approach would be to still use calibrated p-values and increase one's nominal α to decrease type II error. In that case, at least the increase in type I error would be quantifiable. We argue that the best solution is to use designs that have small to no error, as achieved here in this example using a propensity score adjusted new-user cohort design. For such designs the empirical calibration has little effect, and both type I and type II error are, in some sense, optimal. We do not agree with Gruber and Tchetgen that our recommendation that 'observational studies always include negative controls to derive an empirical null distribution and use these to compute calibrated p-values' is premature. Our findings so far suggest that the use of negative controls is a good way to evaluate the bias inherent in a study design, as demonstrated here by comparing a crude and adjusted analysis. The leave-one-out evaluations show that the calibrated p-values provide superior (in the case of large bias) to equal (in the case of almost no bias) calibration properties compared with traditional p-values. We also do not see viable alternatives. For example, the control outcome calibration approach proposed by Gruber and Tchetgen requires a strong exchangeability assumption that the structure and magnitude of the bias is exactly the same for the control and hypothesis of interest. Even if this assumption were to hold true, it remains unknowable to the researcher. Given the large sample size in most observational studies, even small bias can 'distort the p-values beyond repair'. 4 Interpretation of results of observational studies is impossible without quantifying the bias, and we currently see empirical calibration as the only viable means to do this. We believe empirical calibration should always be used and presented in observational studies. To facilitate this, we have created an R package called EmpiricalCalibration (available in Comprehensive R Archive Network (CRAN)) and are working on a tool to quickly identify candidate negative controls. Drs Schuemie and Ryan are employees of Janssen Research and Development, LLC. Drs Madigan and Suchard are partially supported by National Science Foundation grant IIS 1251151. Supporting info item Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. *(abstract via OpenAlex)*

SiM Diagnostics & Prediction Testing & Uncertainty · 发表于 2016-09-04

P‐values and decision‐making: discussion of ‘Limitations of empirical calibration of p‐values using observational data’

Jessica M. Franklin

摘要

Gruber and Tchetgen Tchetgen bring up many important limitations of p‐value calibration as applied to the assessment of the safety and effectiveness of medications in secondary administrative data. In this discussion, I further examine the role of study design and selection of comparators in interpreting p‐value calibration results, and we consider the advantages and disadvantages of automation in the epidemiology of medications, including p‐value calibration. Copyright © 2016 John Wiley & Sons, Ltd.

SiM Longitudinal Data Survival Analysis Nonparametric & Semiparametric · 发表于 2016-09-04

Bayesian quantile regression-based nonlinear mixed-effects joint models for time-to-event and longitudinal data with multiple features

Yangxin Huang, Jiaqing Chen

摘要

This article explores Bayesian joint models for a quantile of longitudinal response, mismeasured covariate and event time outcome with an attempt to (i) characterize the entire conditional distribution of the response variable based on quantile regression that may be more robust to outliers and misspecification of error distribution; (ii) tailor accuracy from measurement error, evaluate non-ignorable missing observations, and adjust departures from normality in covariate; and (iii) overcome shortages of confidence in specifying a time-to-event model. When statistical inference is carried out for a longitudinal data set with non-central location, non-linearity, non-normality, measurement error, and missing values as well as event time with being interval censored, it is important to account for the simultaneous treatment of these data features in order to obtain more reliable and robust inferential results. Toward this end, we develop Bayesian joint modeling approach to simultaneously estimating all parameters in the three models: quantile regression-based nonlinear mixed-effects model for response using asymmetric Laplace distribution, linear mixed-effects model with skew-t distribution for mismeasured covariate in the presence of informative missingness and accelerated failure time model with unspecified nonparametric distribution for event time. We apply the proposed modeling approach to analyzing an AIDS clinical data set and conduct simulation studies to assess the performance of the proposed joint models and method. Copyright © 2016 John Wiley & Sons, Ltd. *(abstract via PubMed)*

Biometrika High-Dimensional · 发表于 2016-09-03

Sparse envelope model: efficient estimation and response variable selection in multivariate linear regression

Z. Su, G. Zhu, X. Chen, Y. Yang

摘要

The envelope model allows efficient estimation in multivariate linear regression. In this paper, we propose the sparse envelope model, which is motivated by applications where some response variables are invariant with respect to changes of the predictors and have zero regression coefficients. The envelope estimator is consistent but not sparse, and in many situations it is important to identify the response variables for which the regression coefficients are zero. The sparse envelope model performs variable selection on the responses and preserves the efficiency gains offered by the envelope model. Response variable selection arises naturally in many applications, but has not been studied as thoroughly as predictor variable selection. In this paper, we discuss response variable selection in both the standard multivariate linear regression and the envelope contexts. In response variable selection, even if a response has zero coefficients, it should still be retained to improve the estimation efficiency of the nonzero coefficients. This is different from the practice in predictor variable selection. We establish consistency and the oracle property and obtain the asymptotic distribution of the sparse envelope estimator. *(abstract via OpenAlex)*

Biometrika Networks & Graphs Genetics & Omics High-Dimensional · 发表于 2016-09-03

Joint estimation of multiple dependent Gaussian graphical models with applications to mouse genomics

Yuying Xie, Yufeng Liu, William Valdar

摘要

Gaussian graphical models are widely used to represent conditional dependence among random variables. In this paper, we propose a novel estimator for data arising from a group of Gaussian graphical models that are themselves dependent. A motivating example is that of modeling gene expression collected on multiple tissues from the same individual: here the multivariate outcome is affected by dependencies acting not only at the level of the specific tissues, but also at the level of the whole body; existing methods that assume independence among graphs are not applicable in this case. To estimate multiple dependent graphs, we decompose the problem into two graphical layers: the systemic layer, which affects all outcomes and thereby induces cross-graph dependence, and the category-specific layer, which represents graph-specific variation. We propose a graphical EM technique that estimates both layers jointly, establish estimation consistency and selection sparsistency of the proposed estimator, and confirm by simulation that the EM method is superior to a simple one-step method. We apply our technique to mouse genomics data and obtain biologically plausible results. *(abstract via PubMed)*

Biometrika Testing & Uncertainty Functional Data · 发表于 2016-09-03

Bootstrap-based testing of equality of mean functions or equality of covariance operators for functional data

E. Paparoditis, T. Sapatinas

摘要

We investigate the properties of a simple bootstrap method for testing the equality of mean functions or of covariance operators in functional data. Theoretical size and power results are derived for certain test statistics, whose limiting distributions depend on unknown infinite-dimensional parameters. Simulations demonstrate good size and power of the bootstrap-based functional tests. *(abstract via OpenAlex)*

Biometrika High-Dimensional Genetics & Omics · 发表于 2016-09-03

An adaptive two-sample test for high-dimensional means

Gongjun Xu, Lifeng Lin, Peng Wei, Wei Pan

摘要

Several two-sample tests for high-dimensional data have been proposed recently, but they are powerful only against certain limited alternative hypotheses. In practice, since the true alternative hypothesis is unknown, it is unclear how to choose a powerful test. We propose an adaptive test that maintains high power across a wide range of situations, and study its asymptotic properties. Its finite sample performance is compared with existing tests. We apply it and other tests to detect possible associations between bipolar disease and a large number of single nucleotide polymorphisms on each chromosome based on a genome-wide association study dataset. Numerical studies demonstrate the superior performance and high power of the proposed test across a wide spectrum of applications. *(abstract via PubMed)*

Biometrika Other · 发表于 2016-09-03

A theoretical study of Stein's covariance estimator

Bala Rajaratnam, Dario Vincenzi

摘要

Stein proposed an estimator to address the poor performance of the sample covariance matrix for samples of small size. The estimator does not impose sparsity conditions and uses an isotonizing algorithm to preserve the order of the sample eigenvalues. Despite its superior numerical performance, its theoretical properties are not well understood. We demonstrate that Stein's covariance estimator gives modest risk reductions when it is not isotonized, and when it is isotonized the risk reductions are significant. Three broad regimes of the estimator's behaviour are identified. *(abstract via OpenAlex)*

JRSSB Causal Inference Survival Analysis · 发表于 2016-09-02

On Estimation of Optimal Treatment Regimes for Maximizingt-Year Survival Probability

Runchao Jiang, Wenbin Lu, Rui Song, Marie Davidian

摘要

Summary: A treatment regime is a deterministic function that dictates personalized treatment based on patients’ individual prognostic information. There is increasing interest in finding optimal treatment regimes, which determine treatment at one or more treatment decision points to maximize expected long-term clinical outcomes, where larger outcomes are preferred. For chronic diseases such as cancer or human immunodeficiency virus infection, survival time is often the outcome of interest, and the goal is to select treatment to maximize survival probability. We propose two non-parametric estimators for the survival function of patients following a given treatment regime involving one or more decisions, i.e. the so-called value. On the basis of data from a clinical or observational study, we estimate an optimal regime by maximizing these estimators for the value over a prespecified class of regimes. Because the value function is very jagged, we introduce kernel smoothing within the estimator to improve performance. Asymptotic properties of the proposed estimators of value functions are established under suitable regularity conditions, and simulation studies evaluate the finite sample performance of the regime estimators. The methods are illustrated by application to data from an acquired immune deficiency syndrome clinical trial.

JRSSB Bayesian Methods · 发表于 2016-09-02

Bayesian Inference for Matérn Repulsive Processes

Vinayak Rao, Ryan P. Adams, David D. Dunson

摘要

Summary: In many applications involving point pattern data, the Poisson process assumption is unrealistic, with the data exhibiting a more regular spread. Such repulsion between events is exhibited by trees for example, because of competition for light and nutrients. Other examples include the locations of biological cells and cities, and the times of neuronal spikes. Given the many applications of repulsive point processes, there is a surprisingly limited literature developing flexible, realistic and interpretable models, as well as efficient inferential methods. We address this gap by developing a modelling framework around the Matérn type III repulsive process. We consider some extensions of the original Matérn type III process for both the homogeneous and the inhomogeneous cases. We also derive the probability density of this generalized Matérn process, allowing us to characterize the conditional distribution of the various latent variables, and leading to a novel and efficient Markov chain Monte Carlo algorithm. We apply our ideas to data sets of spatial locations of trees, nerve fibre cells and Greyhound bus stations.

SMMR Survival Analysis High-Dimensional · 发表于 2016-09-01

Parametric and penalized generalized survival models

Xing-Rong Liu, Yudi Pawitan, Mark Clements

摘要

We describe generalized survival models, where g( S( t| z)), for link function g, survival S, time t, and covariates z, is modeled by a linear predictor in terms of covariate effects and smooth time effects. These models include proportional hazards and proportional odds models, and extend the parametric Royston–Parmar models. Estimation is described for both fully parametric linear predictors and combinations of penalized smoothers and parametric effects. The penalized smoothing parameters can be selected automatically using several information criteria. The link function may be selected based on prior assumptions or using an information criterion. We have implemented the models in R. All of the penalized smoothers from the mgcv package are available for smooth time effects and smooth covariate effects. The generalized survival models perform well in a simulation study, compared with some existing models. The estimation of smooth covariate effects and smooth time-dependent hazard or odds ratios is simplified, compared with many non-parametric models. Applying these models to three cancer survival datasets, we find that the proportional odds model is better than the proportional hazards model for two of the datasets.

SMMR Other · 发表于 2016-09-01

Mortality and morbidity peaks modeling: An extreme value theory approach

Y Chiu, F Chebana, B Abdous, D Bélanger, P Gosselin

摘要

Hospitalizations and deaths belong to the most studied health variables in public health. Those variables are usually analyzed through mean events and trends, based on the whole dataset. However, this approach is not appropriate to comprehend health outcome peaks which are unusual events that strongly impact the health care network (e.g. overflow in hospital emergency rooms). Peaks can also be of interest in etiological research, for instance when analyzing relationships with extreme exposures (meteorological conditions, air pollution, social stress, etc.). Therefore, this paper aims at modeling health variables exclusively through the peaks, which is rarely done except over short periods. Establishing a rigorous and general methodology to identify peaks is another goal of this study. To this end, the extreme value theory appears adequate with statistical tools for selecting and modeling peaks. Selection and analysis for deaths and hospitalizations peaks using extreme value theory have not been applied in public health yet. Therefore, this study also has an exploratory goal. A declustering procedure is applied to the raw data in order to meet extreme value theory requirements. The application is done on hospitalization and death peaks for cardiovascular diseases, in the Montreal and Quebec metropolitan communities (Canada) for the period 1981–2011. The peak return levels are obtained from the modeling and can be useful in hospital management or planning future capacity needs for health care facilities, for example. This paper focuses on one class of diseases in two cities, but the methodology can be applied to any other health peaks series anywhere, as it is data driven.

SMMR Nonparametric & Semiparametric · 发表于 2016-09-01

Modelling retinal pulsatile blood flow from video data

Brigid Betz-Stablein, Martin L Hazelton, William H Morgan

摘要

Modern day datasets continue to increase in both size and diversity. One example of such ‘big data’ is video data. Within the medical arena, more disciplines are using video as a diagnostic tool. Given the large amount of data stored within a video image, it is one of most time consuming types of data to process and analyse. Therefore, it is desirable to have automated techniques to extract, process and analyse data from video images. While many methods have been developed for extracting and processing video data, statistical modelling to analyse the outputted data has rarely been employed. We develop a method to take a video sequence of periodic nature, extract the RGB data and model the changes occurring across the contiguous images. We employ harmonic regression to model periodicity with autoregressive terms accounting for the error process associated with the time series nature of the data. A linear spline is included to account for movement between frames. We apply this model to video sequences of retinal vessel pulsation, which is the pulsatile component of blood flow. Slope and amplitude are calculated for the curves generated from the application of the harmonic model, providing clinical insight into the location of obstruction within the retinal vessels. The method can be applied to individual vessels, or to smaller segments such as 2 × 2 pixels which can then be interpreted easily as a heat map.

SMMR Clinical Trials Bayesian Methods Meta-Analysis & Data Integration · 发表于 2016-09-01

Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials

Joseph S Koopmeiners, Brian P Hobbs

摘要

Randomized, placebo-controlled clinical trials are the gold standard for evaluating a novel therapeutic agent. In some instances, it may not be considered ethical or desirable to complete a placebo-controlled clinical trial and, instead, the placebo is replaced by an active comparator with the objective of showing either superiority or non-inferiority to the active comparator. In a non-inferiority trial, the experimental treatment is considered non-inferior if it retains a pre-specified proportion of the effect of the active comparator as represented by the non-inferiority margin. A key assumption required for valid inference in the non-inferiority setting is the constancy assumption, which requires that the effect of the active comparator in the non-inferiority trial is consistent with the effect that was observed in previous trials. It has been shown that violations of the constancy assumption can result in a dramatic increase in the rate of incorrectly concluding non-inferiority in the presence of ineffective or even harmful treatment. In this paper, we illustrate how Bayesian hierarchical modeling can be used to facilitate multi-source smoothing of the data from the current trial with the data from historical studies, enabling direct probabilistic evaluation of the constancy assumption. We then show how this result can be used to adapt the non-inferiority margin when the constancy assumption is violated and present simulation results illustrating that our method controls the type-I error rate when the constancy assumption is violated, while retaining the power of the standard approach when the constancy assumption holds. We illustrate our adaptive procedure using a non-inferiority trial of raltegravir, an antiretroviral drug for the treatment of HIV.

SMMR Meta-Analysis & Data Integration Networks & Graphs · 发表于 2016-09-01

Continuously updated network meta-analysis and statistical monitoring for timely decision-making

Adriani Nikolakopoulou, Dimitris Mavridis, Matthias Egger, Georgia Salanti

摘要

Pairwise and network meta-analysis (NMA) are traditionally used retrospectively to assess existing evidence. However, the current evidence often undergoes several updates as new studies become available. In each update recommendations about the conclusiveness of the evidence and the need of future studies need to be made. In the context of prospective meta-analysis future studies are planned as part of the accumulation of the evidence. In this setting, multiple testing issues need to be taken into account when the meta-analysis results are interpreted. We extend ideas of sequential monitoring of meta-analysis to provide a methodological framework for updating NMAs. Based on the z-score for each network estimate (the ratio of effect size to its standard error) and the respective information gained after each study enters NMA we construct efficacy and futility stopping boundaries. A NMA treatment effect is considered conclusive when it crosses an appended stopping boundary. The methods are illustrated using a recently published NMA where we show that evidence about a particular comparison can become conclusive via indirect evidence even if no further trials address this comparison.

SMMR Testing & Uncertainty Clinical Trials · 发表于 2016-09-01

Confidence and coverage for Bland–Altman limits of agreement and their approximate confidence intervals

Andrew Carkeet, Yee Teng Goh

摘要

Bland and Altman described approximate methods in 1986 and 1999 for calculating confidence limits for their 95% limits of agreement, approximations which assume large subject numbers. In this paper, these approximations are compared with exact confidence intervals calculated using two-sided tolerance intervals for a normal distribution. The approximations are compared in terms of the tolerance factors themselves but also in terms of the exact confidence limits and the exact limits of agreement coverage corresponding to the approximate confidence interval methods. Using similar methods the 50th percentile of the tolerance interval are compared with the k values of 1.96 and 2, which Bland and Altman used to define limits of agreements (i.e. [Formula: see text]+/− 1.96S d and [Formula: see text]+/− 2S d ). For limits of agreement outer confidence intervals, Bland and Altman’s approximations are too permissive for sample sizes <40 (1999 approximation) and <76 (1986 approximation). For inner confidence limits the approximations are poorer, being permissive for sample sizes of <490 (1986 approximation) and all practical sample sizes (1999 approximation). Exact confidence intervals for 95% limits of agreements, based on two-sided tolerance factors, can be calculated easily based on tables and should be used in preference to the approximate methods, especially for small sample sizes.

SMMR Clinical Trials Bayesian Methods · 发表于 2016-09-01

Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing’s sarcoma

P Dutton, SB Love, L Billingham, AB Hassan

摘要

Trials run in either rare diseases, such as rare cancers, or rare sub-populations of common diseases are challenging in terms of identifying, recruiting and treating sufficient patients in a sensible period. Treatments for rare diseases are often designed for other disease areas and then later proposed as possible treatments for the rare disease after initial phase I testing is complete. To ensure the trial is in the best interests of the patient participants, frequent interim analyses are needed to force the trial to stop promptly if the treatment is futile or toxic. These non-definitive phase II trials should also be stopped for efficacy to accelerate research progress if the treatment proves to be particularly promising. In this paper, we review frequentist and Bayesian methods that have been adapted to incorporate two binary endpoints and frequent interim analyses. The Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma (LINES) is used as a motivating example and provides a suitable platform to compare these approaches. The Bayesian approach provides greater design flexibility, but does not provide additional value over the frequentist approaches in a single trial setting when the prior is non-informative. However, Bayesian designs are able to borrow from any previous experience, using prior information to improve efficiency.

SMMR Bayesian Methods Survival Analysis Causal Inference · 发表于 2016-09-01

A two-stage model in a Bayesian framework to estimate a survival endpoint in the presence of confounding by indication

Carine Bellera, Cécile Proust-Lima, Lawrence Joseph, Pierre Richaud, Jeremy Taylor, Howard Sandler, James Hanley, Simone Mathoulin-Pélissier

摘要

Background: Biomarker series can indicate disease progression and predict clinical endpoints. When a treatment is prescribed depending on the biomarker, confounding by indication might be introduced if the treatment modifies the marker profile and risk of failure. Objective: Our aim was to highlight the flexibility of a two-stage model fitted within a Bayesian Markov Chain Monte Carlo framework. For this purpose, we monitored the prostate-specific antigens in prostate cancer patients treated with external beam radiation therapy. In the presence of rising prostate-specific antigens after external beam radiation therapy, salvage hormone therapy can be prescribed to reduce both the prostate-specific antigens concentration and the risk of clinical failure, an illustration of confounding by indication. We focused on the assessment of the prognostic value of hormone therapy and prostate-specific antigens trajectory on the risk of failure. Methods: We used a two-stage model within a Bayesian framework to assess the role of the prostate-specific antigens profile on clinical failure while accounting for a secondary treatment prescribed by indication. We modeled prostate-specific antigens using a hierarchical piecewise linear trajectory with a random changepoint. Residual prostate-specific antigens variability was expressed as a function of prostate-specific antigens concentration. Covariates in the survival model included hormone therapy, baseline characteristics, and individual predictions of the prostate-specific antigens nadir and timing and prostate-specific antigens slopes before and after the nadir as provided by the longitudinal process. Results: We showed positive associations between an increased prostate-specific antigens nadir, an earlier changepoint and a steeper post-nadir slope with an increased risk of failure. Importantly, we highlighted a significant benefit of hormone therapy, an effect that was not observed when the prostate-specific antigens trajectory was not accounted for in the survival model. Conclusion: Our modeling strategy was particularly flexible and accounted for multiple complex features of longitudinal and survival data, including the presence of a random changepoint and a time-dependent covariate.

SMMR Longitudinal Data Survival Analysis Latent Variables & Mixtures · 发表于 2016-09-01

A joint model for longitudinal and survival data based on an AR(1) latent process

Silvia Bacci, Francesco Bartolucci, Silvia Pandolfi

摘要

A critical problem in repeated measurement studies is the occurrence of nonignorable missing observations. A common approach to deal with this problem is joint modeling the longitudinal and survival processes for each individual on the basis of a random effect that is usually assumed to be time constant. We relax this hypothesis by introducing time-varying subject-specific random effects that follow a first-order autoregressive process, AR(1). We also adopt a generalized linear model formulation to accommodate for different types of longitudinal response (i.e. continuous, binary, count) and we consider some extended cases, such as counts with excess of zeros and multivariate outcomes at each time occasion. Estimation of the parameters of the resulting joint model is based on the maximization of the likelihood computed by a recursion developed in the hidden Markov literature. This maximization is performed on the basis of a quasi-Newton algorithm that also provides the information matrix and then standard errors for the parameter estimates. The proposed approach is illustrated through a Monte Carlo simulation study and the analysis of certain medical datasets.

SMMR Econometrics & Economics · 发表于 2016-09-01

A basket two-part model to analyze medical expenditure on interdependent multiple sectors

Shinya Sugawara, Tianyi Wu, Kenji Yamanishi

摘要

This study proposes a novel statistical methodology to analyze expenditure on multiple medical sectors using consumer data. Conventionally, medical expenditure has been analyzed by two-part models, which separately consider purchase decision and amount of expenditure. We extend the traditional two-part models by adding the step of basket analysis for dimension reduction. This new step enables us to analyze complicated interdependence between multiple sectors without an identification problem. As an empirical application for the proposed method, we analyze data of 13 medical sectors from the Medical Expenditure Panel Survey. In comparison with the results of previous studies that analyzed the multiple sector independently, our method provides more detailed implications of the impacts of individual socioeconomic status on the composition of joint purchases from multiple medical sectors; our method has a better prediction performance.

SiM Bayesian Methods Survival Analysis · 发表于 2016-08-31

Objective Bayesian model selection for Cox regression

Leonhard Held, Isaac Gravestock, Daniel Sabanés Bové

摘要

There is now a large literature on objective Bayesian model selection in the linear model based on theg‐prior. The methodology has been recently extended to generalized linear models using test‐based Bayes factors. In this paper, we show that test‐based Bayes factors can also be applied to the Cox proportional hazards model. If the goal is to select a single model, then both the maximuma posterioriand the median probability model can be calculated. For clinical prediction of survival, we shrink the model‐specific log hazard ratio estimates with subsequent calculation of the Breslow estimate of the cumulative baseline hazard function. A Bayesian model average can also be employed. We illustrate the proposed methodology with the analysis of survival data on primary biliary cirrhosis patients and the development of a clinical prediction model for future cardiovascular events based on data from the Second Manifestations of ARTerial disease (SMART) cohort study. Cross‐validation is applied to compare the predictive performance with alternative model selection approaches based on Harrell's c‐Index, the calibration slope and the integrated Brier score. Finally, a novel application of Bayesian variable selection to optimal conditional prediction via landmarking is described. Copyright © 2016 John Wiley & Sons, Ltd.

SiM Other · 发表于 2016-08-31

Estimation for zero-inflated over-dispersed count data model with missing response

Rajibul Mian, Sudhir Paul

摘要

In this paper, we develop estimation procedure for the parameters of a zero-inflated over-dispersed/under-dispersed count model in the presence of missing responses. In particular, we deal with a zero-inflated extended negative binomial model in the presence of missing responses. A weighted expectation maximization algorithm is used for the maximum likelihood estimation of the parameters involved. Some simulations are conducted to study the properties of the estimators. Robustness of the procedure is shown when count data follow other over-dispersed models, such as the log-normal mixture of the Poisson distribution or even from a zero-inflated Poisson model. An illustrative example and a discussion leading to some conclusions are given. Copyright © 2016 John Wiley & Sons, Ltd. *(abstract via PubMed)*

SiM Diagnostics & Prediction · 发表于 2016-08-31

A simple and robust method for multivariate meta‐analysis of diagnostic test accuracy

Yong Chen, Yulun Liu, Haitao Chu, Mei‐Ling Ting Lee, Christopher H. Schmid

摘要

Meta‐analysis of diagnostic test accuracy often involves mixture of case–control and cohort studies. The existing bivariate random‐effects models, which jointly model bivariate accuracy indices (e.g., sensitivity and specificity), do not differentiate cohort studies from case–control studies and thus do not utilize the prevalence information contained in the cohort studies. The recently proposed trivariate generalized linear mixed‐effects models are only applicable to cohort studies, and more importantly, they assume a common correlation structure across studies and trivariate normality on disease prevalence, test sensitivity, and specificity after transformation by some pre‐specified link functions. In practice, very few studies provide justifications of these assumptions, and sometimes these assumptions are violated. In this paper, we evaluate the performance of the commonly used random‐effects model under violations of these assumptions and propose a simple and robust method to fully utilize the information contained in case–control and cohort studies. The proposed method avoids making the aforementioned assumptions and can provide valid joint inferences for any functions of overall summary measures of diagnostic accuracy. Through simulation studies, we find that the proposed method is more robust to model misspecifications than the existing methods. We apply the proposed method to a meta‐analysis of diagnostic test accuracy for the detection of recurrent ovarian carcinoma. Copyright © 2016 John Wiley & Sons, Ltd.

第 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 页